Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Phase 1 in TNBC
NCT02838823Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jul 2016
- Primary completion
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Treatment-related adverse events at 1.5 years. Started Jul 2016; status: completed.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02838823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02838823.